Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Advances in Therapies of Cerebellar Disorders: Immune-mediated Ataxias

Author(s): Marios Hadjivassiliou*

Volume 18, Issue 6, 2019

Page: [423 - 431] Pages: 9

DOI: 10.2174/1871527317666171221110548

Price: $65

Abstract

The identification of an increasing number of immune mediated ataxias suggests that the cerebellum is often a target organ for autoimmune insults. The diagnosis of immune mediated ataxias is challenging as there is significant clinical overlap between immune mediated and other forms of ataxia. Furthermore the classification of immune mediated ataxias requires further clarification particularly for those ataxias where no specific antigenic trigger and associated antibodies have been identified. Recognition of immune mediated ataxias remains imperative as therapeutic interventions can be effective, although given the relative rarity of this entity, large-scale treatment trials may not be feasible. This review will discuss advances in therapies for immune mediated ataxias based on what is currently available in the literature.

Keywords: Cerebellar ataxia, gluten ataxia, paraneoplastic cerebellar degeneration, primary autoimmune cerebellar ataxia, cerebellum, vertebrate nervous system.

« Previous Next »
Graphical Abstract

[1]
Hadjivassiliou M, Martindale J, Shanmugarajah P, et al. Causes of progressive cerebellar ataxia: Prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry 2017; 88(4): 301-9. [doi: 10.1136/jnnp-2016-314863].
[2]
Hadjivassiliou M. Primary autoimmune cerebellar ataxia (PACA). Adv Clin Neurosci Rehabil 2010; 9: 8-11.
[3]
Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological and neuropathological characteristics of gluten ataxia. The Lancet 1998; 352: 1582-5.
[4]
Sarrigiannis PG, Hoggard N, Aeschlimann D, et al. Myoclonus ataxia and refractory coeliac disease. Cerebellum & Ataxias 2014; 1(1): 11.
[5]
Hadjivassiliou M, Sanders DS, Grunewald RA, Woodroofe N, Boscolo S, Aeschlimann D. Gluten sensitivity: from gut to brain. Lancet Neurol 2010; 9: 318-30.
[6]
Hadjivassiliou M, Sanders DS, Aeschlimann D. The neuroimmunology of gluten intolerance. In:Neuro-Immuno-Gastroenterology Springer, Cham. 2016; pp. 263-85.
[7]
Hadjivassiliou M, Grünewald RA, Sanders DS, Shanmugarajah P, Hoggard N. Effect of gluten-free diet on cerebellar MR spectroscopy in gluten ataxia. Neurology 2017; 89(7): 705-9.
[8]
Beversdorf D, Moses P, Reeves A, et al. A man with weight loss, ataxia, and confusion for 3 months. The Lancet 1996; 347: 448.
[9]
Hahn JS, Sum JM, Bass D, et al. Celiac disease presenting as gait disturbance and ataxia in infancy. J Child Neurol 1998; 13: 351-3.
[10]
Pellecchia MT, Scala R, Perretti A. Cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet. Neurology 1999; 53: 1606-7.
[11]
Sander HW, Magda P, Chin RL, et al. Cerebellar ataxia and celiac disease. The Lancet 2003; 362: 1548.
[12]
Bürk K, Melms A, Schulz JB. Effectiveness of intravenous immunoglobulin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 2001; 50: 827-8.
[13]
Souayah N, Chin RL, Brannagan TH, Latov N, Green PHR, Kokoszka A. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 2008; 15: 1300-3.
[14]
Nanri K, Okita M, Takeguchi M, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med Tokyo Jpn 2009; 48: 783-90.
[15]
Hadjivassiliou M, Davies-Jones GAB, Sanders DS, et al. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003; 74(9): 1221-4.
[16]
Hadjivassiliou M, Rao DG, Grunewald RA, et al. Neurological dysfunction in coeliac disease and non-coeliac gluten sensitivity. Am J Gastroenterol 2016; 111(4): 561.
[17]
Hadjivassiliou M, Sanders DS, Aeschlimann DP. Gluten-related disorders: Gluten ataxia. Dig Dis 2015; 33: 264-8.
[18]
Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80: 1-6.
[19]
Hadjivassiliou M. Cerebellum and immune diseases. In: M Manto, Ed.. Handbook of cerebellum and cerebellar disorders. Springer 2013; pp. 1-2424.
[20]
Lu CS, Thompson PD, Quinn NP, et al. Ramsay Hunt syndrome and celiac disease: A new association? Mov Disord 1986; 1: 209-19.
[21]
Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-40.
[22]
Hadjivassiliou M, Alder SJ, Van Beek EJR, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a six year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009; 119: 186-93.
[23]
Dropcho EJ. Principles of paraneoplastic syndromes. Ann N Y Acad Sci 1998; 841: 246-61.
[24]
Candler PM, Hart PE, Barnett M, Weil R, Ress JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75: 1411-5.
[25]
Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-82.
[26]
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. IA clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-7.
[27]
Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713-5.
[28]
Shams’ili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126(Pt 6): 1409-18.
[29]
Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol 2016; 3: 655-63.
[30]
Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76: 705-10.
[31]
Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol 2013; 15: 185-200.
[32]
Kerr Dib. Ong J. GABA receptors. Pharmacol Ther 1995; 67: 187-246.
[33]
Ellis TM, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med 1996; 2: 148-53.
[34]
Solimena M, Piccolo G, Martino G. Autoantibodies directed against gabaminergic nerve terminals in a patient with idiopathic late-onset cerebellar ataxia and type 1 diabetes mellitus. Clin Neuropathol 1998; 7(Suppl.): 211.
[35]
Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Arch Neurol 2001; 58: 225-30.
[36]
Lilleker JB, Biswas V, Mohanraj R. Glutamic acid secarboxylase (GAD) antibodies in epilepsy: Diagnostic yield and therapeutic implications. Seizure 2014; 23: 598-602.
[37]
Arino H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies; immune profile and long-term effect of immunotherapy. JAMA Neurol 2014; 71(8): 1009-16.
[38]
Mitoma H, Manto M, Hampe CS. Pathogenic roles of glutamic acid decarboxylase 65 autoantibodies in cerebellar ataxias. J Immunolog Research 2017. 2017.
[39]
Hadjivassiliou M, Boscolo S, Tongiorgi E, et al. Cerebellar ataxia as a possible organ specific autoimmune disease. Mov Disord 2008; 23(10): 1270-377.
[40]
Pugliese A, Solimena M, Awdeh ZL, et al. Association of HLA-DQB1 0201 with stiff-man syndrome. J Clin Endocrinol Metab 1993; 77: 1550-3.
[41]
Serjeantson SW, Court J, Mackay IR, et al. HLA-DQ genotypes are associated with autoimmunity to glutamic acid decarboxylase in insulin-dependent diabetes mellitus patients. Hum Immunol 1993; 38: 97-104.
[42]
Segni M, Pani MA, Pasquino AM, et al. Familial clustering of juvenile thyroid autoimmunity: Higher risk is conferred by human leukocyte antigen DR3-DQ2 and thuroid peroxidase antibody status in fathers. J Clin Endocrinol Metab 2002; 87: 3779-82.
[43]
Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350: 2068-79.
[44]
Selim M, Drachman DA. Ataxia associated with Hashimoto’s disease: Progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001; 71: 81-7.
[45]
Wong S, Pollock AN, Burnham JM, et al. Acute cerebellar ataxia due to Sjogren’s syndrome. Neurol 2004; 62: 2332-3.
[46]
Trivedi R, Mundanthanam G, Amyes E, et al. Autoantibody screening in subacute cerebellar ataxia. Lancet 2000; 356: 565-6.
[47]
Zuliani L, Sabater L, Saiz A, et al. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurol 2007; 68: 239-40.
[48]
Shiihara T, Kato M, Konno A, et al. Acute cerebellar ataxia and consecutive cerebellitis produced by glutamate receptor ∂ 2 autoantibody. Brain Dev 2007; 29: 254-6.
[49]
Bürk K, Wick M, Roth G, et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257: 59-62.
[50]
Jarius S, Wandinger KP, Horn S, et al. A new Purkinje cell antibody associated with subacute cerebellar ataxia: Immunological characterisation. J Neuroinflammation 2010; 7: 21.
[51]
Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for the treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias 2015; 2: 14.
[52]
Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxia. Cerebellum 2016; 15(2): 213-32.
[53]
Takeguchi M, Nanri K, Okita M, et al. Efficacy of intravenous immunoglobulin for slowly progressive cerebellar atrophy. Rinsho Shinkeigaku (Japanese) 2006; 46: 467-74.
[54]
Jones AL, Flanagan EP, Pittock SJ, et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol 2015; 72: 1304-12.
[55]
Pang KK, De Sousa C, Lang B, et al. A prospective study of the presentation and management of dancing eye syndrome/ opsoclonus-myoclonus syndrome in the UK. Eur J Paediatr Neurol 2009; 14: 156-61.
[56]
Deconinck N, Scaillon M, Segers V, et al. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol 2006; 34: 312-4.
[57]
Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 437-43.
[58]
Klaas JP, Ahiskog JE, Pittock SJ, et al. Adult onset opsoclonus-myoclonus syndrome. Arch Neurol 2012; 69: 1598.
[59]
Pranzatelli MR, Travelstead BS, Tate ED, et al. B and T-cell markers in opsoclonus-myoclonus syndrome. Neurology 2004; 62: 1526-32.
[60]
Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus myolconus. Mov Disord 2010; 25: 238-42.

Rights & Permissions Print Cite
Article Metrics
71
6
1
1
© 2024 Bentham Science Publishers | Privacy Policy